Secuencia de tratamiento de llegada de la inmunoterapia en CPNM metastásico

20 / 34

IMPower 131 Trial – Overall Survival
Minimum follow-up: 9.8
mo
Median follow-up: 17.1
mo
Time (months)
12.0
%
24.
7%
12-month PFS
Presented By Robert Jotte at 2018 ASCO Annual Meeting